Medical devices company Varian (NYSE:VAR) reported on Monday the receipt of approval from the Taiwan FDA for its new cancer treatment system, Halcyon.

This approval allows the company to market Halcyon in Taiwan as well as further expands its global availability and high-quality, cost-effective cancer treatments.

An advanced cancer treatment system with a human-centred and user-friendly design, Halcyon is engineered to revolutionise clinical workflow, accelerate installation timeframes, expedite commissioning, simplify training and automate treatment, enhance most aspects of image-guided volumetric intensity modulated radiotherapy (IMRT) and offer advanced treatments for lung, esophagus, brain, head & neck, as well as many other forms of cancer.

Halcyon's design has shown to enhance patient comfort and increase the treatment efficiency. With the streamlined workflow, the system only requires nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies, added the company.

In conjunction, Halcyon has received FDA 510(k) clearance in the US, CE mark in Europe, Shonin approval in Japan and ANVISA registration in Brazil since its launch in May 2017.